Stoke Therapeutics, Inc. Logo

Stoke Therapeutics, Inc.

Developing RNA-based medicines for genetic diseases by increasing protein from the healthy gene.

STOK | US

Overview

Corporate Details

ISIN(s):
US86150R1077
LEI:
Country:
United States of America
Address:
45 WIGGINS AVENUE, 1730 BEDFORD
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Stoke Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing RNA-based medicines to treat severe genetic diseases. The company's proprietary research platform, TANGO (Targeted Augmentation of Nuclear Gene Output), aims to restore normal protein levels by increasing—or "stoking"—protein expression from the healthy copy of a mutated gene. This approach is primarily designed to address haploinsufficiencies, where a single functional gene is insufficient to prevent disease. Stoke's lead candidate, zorevunersen (STK-001), is in clinical development for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. The company's pipeline also includes programs for other genetic disorders, such as autosomal dominant optic atrophy (ADOA).

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Stoke Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Stoke Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Stoke Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Protalix BioTherapeutics, Inc. Logo
Develops plant-cell-based protein therapies for rare diseases like Gaucher and Fabry.
United States of America
PLX
Protara Therapeutics, Inc. Logo
Clinical-stage biotech developing cell therapies for cancer and rare diseases.
United States of America
TARA
PROTEINA CO.,LTD. Logo
A biotech firm specializing in proteomics for drug discovery and diagnostics in oncology.
South Korea
468530
PROTIA INC. Logo
Develops IVD kits and instruments for allergy, POCT, infectious & autoimmune diseases.
South Korea
303360
Psych Capital Plc Logo
A life sciences firm developing psilocybin treatments for anorexia and mental health conditions.
United Kingdom
PSY
PSYENCE BIOMEDICAL LTD. Logo
Developing natural psilocybin therapies for anxiety and depression in palliative care.
United States of America
PBM
PTC THERAPEUTICS, INC. Logo
Develops and commercializes pioneering medicines for patients with rare diseases.
United States of America
PTCT
Pulmatrix, Inc. Logo
Develops inhaled therapies for respiratory and CNS disorders using its iSPERSE™ technology.
United States of America
PULM
PUMA BIOTECHNOLOGY, INC. Logo
Develops and commercializes innovative cancer therapeutics, with an approved drug and a clinical pipeline.
United States of America
PBYI
Pure Biologics S.A. Logo
Develops novel antibody & aptamer drugs for immuno-oncology and autoimmune diseases.
Poland
PUR

Talk to a Data Expert

Have a question? We'll get back to you promptly.